全球调查:高危非肌层浸润性膀胱癌真实世界根治性膀胱切除术使用情况
该跨国横断面调查纳入8国359名医生报告的2583例高危非肌层浸润性膀胱癌患者,评估根治性膀胱切除术的真实使用情况。BCG一线治疗占58%,复发患者二至四线RC使用仅7%–8%,医生认为24%患者为未来可能RC候选者;BCG治疗患者中20%被提供RC但68%拒绝,主因生活质量、造口及手术安全顾虑。
要点
- 真实世界中高危NMIBC的RC使用率低,与指南推荐存在差距
- 复发患者二至四线RC使用率仅7%–8%
- 被提供RC的患者中68%拒绝,主因生活质量与造口顾虑
核心结论
- 尽管有指南推荐,真实世界RC使用率低,多数被提供RC的患者因生活质量与安全顾虑拒绝。
- BCG无应答高危NMIBC患者存在对替代有效保膀胱治疗的未满足需求。
研究设计与样本
- Adelphi疾病特定项目跨国横断面调查,覆盖中国、日本、加拿大、法国、德国、意大利、西班牙和英国。
- 359名泌尿外科与肿瘤内科医生报告2583例高危NMIBC患者数据,平均年龄68.9(标准差9.8)岁,74%男性,T1高级别肿瘤占68%。
主要发现
- BCG作为一线治疗用于58%(n=1487)患者。
- 复发高危NMIBC患者中,RC在二线、三线、四线治疗的使用分别为8%(62/802)、7%(13/188)、8%(4/52)。
- 医生认为24%患者为未来可能的RC候选者。
- BCG治疗患者825例中,169例(20%)被提供RC,其中115例(68%)拒绝;拒绝原因最常见为生活质量顾虑(87%)、不愿造口(60%)、手术安全顾虑(37%)。
临床怎么用
- 应重视高危NMIBC患者对RC的生活质量与造口顾虑,加强术前沟通与决策支持。
- BCG无应答患者需探索替代有效保膀胱治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate real-world utilisation of radical cystectomy (RC), its acceptance and limitations, and physician perspectives on RC in patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC). PATIENTS/SUBJECTS AND METHODS: Data were obtained from the Adelphi Disease Specific Programme™, a multinational, cross-sectional survey of urologists and medical oncologists treating patients with HR-NMIBC in China, Japan, Canada, France, Germany, Italy, Spain, and the UK. Physicians reported patient demographics, clinical characteristics, treatment patterns, and patient preferences regarding HR-NMIBC treatment and surgery. RESULTS: Overall, 359 physicians provided data for 2583 patients (mean [standard deviation] patient age, 68.9 [9.8] years; 74% male; Stage-1 [T1] high-grade tumours 68%). Bacillus Calmette-Guérin (BCG) was used as first-line treatment in 58% (n = 1487) of patients. Among patients with recurrent HR-NMIBC, RC was used in 8% (62 of 802), 7% (13 of 188), and 8% (four of 52) at second line-of-treatment, third line-of-treatment, and fourth line-of-treatment, respectively. Physicians considered 24% of patients likely future RC candidates. Further data were collected on 825 patients who received BCG treatment. Among these patients, RC was offered to 169 (20%); 115 of these patients (68%) refused, most commonly because of quality-of-life concerns (87%), unwillingness to have a stoma (60%), and surgical safety concerns (37%). CONCLUSION: Despite guideline recommendations, real-world RC use was low, and most patients offered RC refused it because of quality-of-life and safety concerns. These findings highlight an unmet need for alternative and efficacious bladder-preserving treatments for patients with BCG-unresponsive HR-NMIBC.
引用
- Escrig JLD, Black P, Inokuchi J, et al. Real-world radical cystectomy use in high-risk non-muscle-invasive bladder cancer: a global survey. BJU Int. 2026. PMID: 42826930. doi:10.1111/bju.70480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。